Crescent Biopharma (CBIO) Cash from Investing Activities (2013 - 2026)
Crescent Biopharma (CBIO) reported Cash from Investing Activities of -$8.1 million for Q1 2026, up 88.71% quarter-over-quarter from -$72.2 million in Q4 2025.
Crescent Biopharma (CBIO) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has 14 years of Cash from Investing Activities data on file, last reported at -$8.1 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$8.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$81.1 million (down 3200294.79% YoY), and the FY2025 annual result was -$72.9 million, down 364185.28% from the prior year.
- Cash from Investing Activities improved to -$8.1 million in Q1 2026 per CBIO's latest filing, from -$72.2 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$1.0 in Q4 2022 and troughed at -$72.2 million in Q4 2025.
- A 5-year average of -$5.8 million and a median of -$9198.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities jumped 99.96% in 2022, then sank 80000.0% in 2023.
- A 5-year view of Cash from Investing Activities shows it stood at -$1.0 in 2022, then slumped by 80000.0% to -$801.0 in 2023, then tumbled by 216.23% to -$2533.0 in 2024, then sank by 2849998.7% to -$72.2 million in 2025, then soared by 88.71% to -$8.1 million in 2026.
- Business Quant data shows CBIO's Cash from Investing Activities at -$8.1 million in Q1 2026, -$72.2 million in Q4 2025, and -$586000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | -8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.15 Mn |
| Mar 31, 2026 | -8.15 Mn |
| Dec 31, 2025 | -72.19 Mn |
| Dec 31, 2025 | -72.19 Mn |
| Sep 30, 2025 | -586,000.00 |
| Sep 30, 2025 | -586,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Jun 30, 2024 | -2,533.00 |
| Jun 30, 2024 | -2,533.00 |
| Mar 31, 2024 | -7,439.00 |
| Mar 31, 2024 | -7,439.00 |
| Dec 31, 2023 | -801.00 |
| Dec 31, 2023 | -801.00 |
| Sep 30, 2023 | -7,866.00 |
| Sep 30, 2023 | -7,866.00 |
| Jun 30, 2023 | -10,530.00 |
| Jun 30, 2023 | -10,530.00 |
| Mar 31, 2023 | -2,197.00 |
| Mar 31, 2023 | -2,197.00 |